Page 60 - GlaxoSmithKline Pharmaceuticals AR 2012

56
Notes to the Financial Statements for the year ended 31st December, 2012 — continued
(iv) Directors and members of GSK India Management Team and their relatives:
Dr. A. Banerjee (up to 31st July, 2012) Mr. R. Bartaria
Mr. A.N. Roy (w.e.f 4th November, 2011) Mr. R.C. Sequeira
Mr. C.T. Renganathan Mr. R.R. Bajaaj
Mr. D.S. Parekh Mr. R. Krishnaswamy (w.e.f. 16th March, 2011)
Mr. D. Sundaram Mr. S. Harford *
Dr. H.B. Joshipura Dr. S. Joglekar
Mr. H. Buch Mr. Sunder Rajan (up to 17th February, 2012)
Mr. K. Hazari (w.e.f. 1st August, 2011) Mr. S. Khanna
Mr. M.B. Kapadia Mrs. S. Patel (up to 23rd May, 2011)
Mr. M.K. Vasanth Kumar (up to 1st August, 2011) Mr. S. Dheri (w.e.f. 1st April, 2012)
Mr. N. Kaviratne Mr. V. Narayanan (up to 9th November, 2012)
Mr. P. Bhide Mr. V. Thyagarajan
Mr. P.V. Nayak
* no transactions during the year
2 The following transactions were carried out with the related parties in the ordinary course of business.
(i) Dividend paid to parties referred to in item 1(i) above:
Rupees in lakhs
2012 2011
Glaxo Group Limited, U.K. .. .. .. .. .. .. .. 137,18.36 121,94.10
Eskaylab Limited, U.K. .. .. .. .. .. .. .. 26,46.00 23,52.00
Burroughs Wellcome International Limited, U.K. .. .. .. .. 15,12.00 13,44.00
Castleton Investment Limited, Mauritius .. .. .. .. .. 14,36.51 12,76.90
(ii) Details relating to parties referred to in items 1(ii) and 1(iii) above:
Rupees in lakhs
Subsidiary of
the company (ii)
Other companies in
the GSK Group (iii)
2012 2011 2012 2011
1 Purchase of materials/traded goods .. .. .. — — 323,49.86 260,95.18
2 Sale of materials/sale of products .. .. .. — — 12,65.97 27,99.65
3 Sale of fixed assets .. .. .. .. .. — — — 74.91
4 Expenses recharged to other companies .. .. 2,84.15 4,90.51 13,61.94 11,72.15
5 Research and development recoveries .. .. — — — 66.25
6 Expenses recharged by other companies .. .. — — 15,70.78 13,77.74
7 Manufacturing charges recovered .. .. .. 49.40 52.00 1,96.85 1,37.01
8 Consignment sales commission received .. .. 75.32 1,41.30 29.85 48.94
9 Clinical research and data management recoveries .. — — 45,41.18 40,96.17
10 Central Value Added Tax credits availed on behalf
of a related party (net) .. .. .. .. — — 48.23 4,58.70
11 Employee benefits transferred to a related party .. — — 13.71 85.46
12 Dividend received .. .. .. .. .. 22,00.00 18,00.00 — —
13 Outstanding (payables)/receivables at the year end (net)# (1,59.05) (1,16.56) (40,31.06) (58,41.35)
# Transactions with the above parties are accounted in the respective current accounts.